These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 17673312)

  • 21. A direct comparison of the natriuretic peptides and their relationship to survival in chronic heart failure of a presumed non-ischaemic origin.
    Stanton E; Hansen M; Wijeysundera HC; Kupchak P; Hall C; Rouleau JL;
    Eur J Heart Fail; 2005 Jun; 7(4):557-65. PubMed ID: 15921795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
    Tang WH; Steinhubl SR; Van Lente F; Brennan D; McErlean E; Maroo A; Francis GS; Topol EJ
    Am Heart J; 2007 Jan; 153(1):36-41. PubMed ID: 17174634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nt-proANP in plasma, a marker of salt sensitivity, is reduced in type 2 diabetes patients.
    Melander O; Frandsen E; Magnusson M; Grubb A; Jovinge S; Groop L
    J Intern Med; 2005 Mar; 257(3):281-8. PubMed ID: 15715685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.
    Shelton RJ; Clark AL; Goode K; Rigby AS; Cleland JG
    Eur Heart J; 2006 Oct; 27(19):2353-61. PubMed ID: 16952921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-terminal pro-brain natriuretic peptide used for the prediction of coronary artery stenosis.
    Wolber T; Maeder M; Rickli H; Riesen W; Binggeli C; Duru F; Ammann P
    Eur J Clin Invest; 2007 Jan; 37(1):18-25. PubMed ID: 17181563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization.
    Sir JJ; Chung WY; Hwang SJ; Kang HJ; Cho YS; Koo BK; Chae IH; Choi DJ; Kim HS; Sohn DW; Kim CH; Oh BH; Park YB; Choi YS
    Int J Cardiol; 2008 Jun; 126(3):322-32. PubMed ID: 17544525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes of serum N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases and its clinical significance].
    Yang CL; Qiu YR; Zhou F; Feng PF
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):866-9. PubMed ID: 18504223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left ventricular dysfunction and NT-proBNP levels in patients with one-vessel disease after first ST-elevation myocardial infarction treated with primary coronary angioplasty.
    Szadkowska I; Pawlicki L; Kowalski J; Banach M; Goch JH; Chizyński K
    Kardiol Pol; 2009 Nov; 67(11):1201-6. PubMed ID: 20024847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.
    Almqvist EG; Becker C; Bondeson AG; Bondeson L; Svensson J; Svensson SE
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):760-6. PubMed ID: 17121527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
    Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
    Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease].
    Zhang SR; Zhang YH; Xu Q; Qiu HX; Chen Q
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jun; 11(6):429-32. PubMed ID: 19558803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Personal experience with determination of NT-proBNP in clinical practice].
    Stejskal D; Oral I; Lacnák B; Juráková R; Horalík D; Adamovská S; Prosková J; Hrabovská I; Ozanová G
    Vnitr Lek; 2003 Feb; 49(2):121-6. PubMed ID: 12728579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma N-terminal protype-B natriuretic peptide levels in risk assessment of patients with mitral regurgitation secondary to ischemic and nonischemic dilated cardiomyopathy.
    Dini FL; Fontanive P; Conti U; Andreini D; Cabani E; De Tommasi SM
    Am Heart J; 2008 Jun; 155(6):1121-7. PubMed ID: 18513528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction.
    Steen H; Futterer S; Merten C; Jünger C; Katus HA; Giannitsis E
    J Cardiovasc Magn Reson; 2007; 9(5):749-58. PubMed ID: 17891611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
    Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
    Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) to distinguish between congestive heart failure and non-cardiac causes of acute dyspnea in cats.
    Fox PR; Oyama MA; Reynolds C; Rush JE; DeFrancesco TC; Keene BW; Atkins CE; Macdonald KA; Schober KE; Bonagura JD; Stepien RL; Kellihan HB; Nguyenba TP; Lehmkuhl LB; Lefbom BK; Moise NS; Hogan DF
    J Vet Cardiol; 2009 May; 11 Suppl 1():S51-61. PubMed ID: 19394287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy.
    Ezekowitz JA; Armstrong PW; Granger CB; Theroux P; Stebbins A; Kim RJ; Patel MR
    Am Heart J; 2010 Aug; 160(2):272-8. PubMed ID: 20691832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction.
    Hammerer-Lercher A; Neubauer E; Müller S; Pachinger O; Puschendorf B; Mair J
    Clin Chim Acta; 2001 Aug; 310(2):193-7. PubMed ID: 11498085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.